Codrituzumab

Drug Profile

Codrituzumab

Alternative Names: GC-33; RG 7686; RO 5137382

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Perseus Proteomics
  • Developer Chugai Pharmaceutical; Roche
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action Glypican 3 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Hepatocellular carcinoma

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for phase-I development in Hepatocellular carcinoma(Combination therapy, Late-stage disease, Metastatic disease) in Taiwan (IV)
  • 04 Nov 2017 No recent reports of development identified for phase-I development in Hepatocellular carcinoma(Combination therapy, Late-stage disease, Metastatic disease) in USA (IV)
  • 01 Aug 2016 Chugai initiates enrolment in a phase I trial for Hepatocellular carcinoma (Combination therapy, Late-stage disease, Metastatic disease) in Taiwan (IV) (JapicCTI163325)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top